Antibiotic-Associated Colitis (Clostridioides difficile)

For the why behind the fact

Use this page to connect what you are memorizing.

Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.

Overview


Plain-Language Overview

Antibiotic-Associated Colitis (Clostridioides difficile) is an infection that affects the large intestine, causing inflammation and irritation. It often happens after taking antibiotics, which can disrupt the normal balance of bacteria in the gut. This disruption allows a harmful bacterium called Clostridioides difficile to grow excessively and produce toxins. These toxins damage the lining of the colon, leading to symptoms like diarrhea, abdominal pain, and fever. The condition can range from mild to severe and may cause serious complications if untreated. It primarily affects the digestive system and can significantly impact a person's health and comfort.

Clinical Definition

Antibiotic-Associated Colitis (Clostridioides difficile) is a condition characterized by inflammation of the colon caused by the overgrowth of the toxin-producing bacterium Clostridioides difficile following disruption of normal gut flora, typically due to antibiotic use. The core pathology involves the production of toxin A and toxin B, which damage colonic epithelial cells, leading to mucosal injury, pseudomembrane formation, and colitis. It is a major cause of nosocomial diarrhea and can result in complications such as toxic megacolon and sepsis. The disease spectrum ranges from mild diarrhea to fulminant colitis. Diagnosis and management are critical due to its high morbidity and potential mortality, especially in hospitalized or immunocompromised patients.

Inciting Event

  • Administration of broad-spectrum antibiotics disrupts normal gut flora allowing C. difficile proliferation.

  • Exposure to C. difficile spores in healthcare settings initiates colonization.

  • Gastrointestinal surgery or instrumentation can predispose to infection by altering mucosal defenses.

Latency Period

  • CDI can begin during antibiotic treatment or weeks to months afterward; do not exclude it because more than 30 days have elapsed. Some cases lack recent antibiotic exposure.

  • Recurrence can occur weeks to months after initial infection due to persistent spores or reinfection.

Diagnostic Delay

  • Attributing diarrhea to other causes such as viral gastroenteritis or antibiotic side effects delays diagnosis.

  • Failure to consider C. difficile in outpatient settings leads to missed early testing.

  • Inadequate stool testing or delayed sample collection can postpone confirmation.

  • Mild or atypical presentations may not prompt immediate evaluation for C. difficile.

Clinical Presentation


Signs & Symptoms

  • Watery diarrhea occurring after recent antibiotic use is the hallmark symptom.

  • Lower abdominal cramping and urgency are common complaints.

  • Fever and malaise often accompany the diarrhea.

  • Nausea and anorexia may be present.

  • Fulminant CDI may cause hypotension, ileus or megacolon; diarrhea can diminish with ileus. Grossly bloody stool is not the typical hallmark and warrants consideration of other causes.

History of Present Illness

  • Watery diarrhea develops after recent antibiotic use, often accompanied by abdominal cramping.

  • Fever and leukocytosis are common systemic signs of infection.

  • Assess dehydration, distension, ileus and systemic toxicity; severe abdominal illness may progress even when stool output falls.

  • Recurrent episodes present with similar symptoms following initial resolution.

Past Medical History

  • Recent antibiotic therapy within the past 2 months is a key historical factor.

  • Previous episodes of C. difficile infection increase risk of recurrence.

  • Hospitalization or residence in long-term care facilities is frequently reported.

  • Underlying chronic illnesses such as inflammatory bowel disease or immunosuppression worsen prognosis.

Family History

  • []

Physical Exam Findings

  • Diffuse abdominal tenderness without peritoneal signs is common in antibiotic-associated colitis.

  • Fever may be present reflecting systemic inflammation.

  • Signs of dehydration such as dry mucous membranes and tachycardia can be observed due to diarrhea.

  • Hyperactive bowel sounds are often noted early in the disease course.

  • Toxic megacolon may present with abdominal distension and decreased bowel sounds in severe cases.

Diagnostic Workup


Diagnostic Criteria

Diagnose symptomatic CDI, usually new unexplained frequent unformed stools, with appropriate positive toxin/toxigenic-organism testing. Recent antibiotics support suspicion but are not mandatory. NAAT can be positive in colonization, so interpret it with symptoms and the local testing algorithm. Avoid testing formed stool, asymptomatic patients or for cure. Fulminant disease with ileus may have little diarrhea.

Pathophysiology


Key Mechanisms

  • Disruption of normal gut microbiota by broad-spectrum antibiotics allows overgrowth of Clostridioides difficile.

  • Toxins A and B glucosylate and inactivate Rho-family GTPases, disrupting the actin cytoskeleton and epithelial barrier and provoking inflammation.

  • Inflammatory response leads to pseudomembrane formation and colitis.

  • Toxin-mediated damage increases intestinal permeability causing diarrhea and systemic symptoms.

InvolvementDetails
Organs

Colon is the main organ affected, exhibiting pseudomembranous inflammation and diarrhea characteristic of antibiotic-associated colitis.

Tissues

Colonic mucosa is the primary site of inflammation and ulceration in antibiotic-associated colitis.

Submucosa becomes edematous and infiltrated by inflammatory cells during active infection.

Cells

Neutrophils mediate acute inflammation and contribute to mucosal damage in antibiotic-associated colitis.

Macrophages release proinflammatory cytokines that exacerbate colonic tissue injury.

Epithelial cells of the colon are damaged by toxins A and B produced by Clostridioides difficile, leading to barrier disruption.

Chemical Mediators

Toxin A and Toxin B are exotoxins produced by Clostridioides difficile that disrupt cytoskeletal integrity and induce inflammation.

Interleukin-8 (IL-8) recruits neutrophils to the site of infection, amplifying mucosal inflammation.

Tumor necrosis factor-alpha (TNF-α) promotes inflammatory responses and tissue injury in the colonic mucosa.

Treatments


Pharmacological Treatments

  • Vancomycin (oral/enteral; rectal adjunct when indicated)

    • Mechanism:
      • Inhibits bacterial cell wall synthesis by binding to D-alanyl-D-alanine termini, effective against Clostridioides difficile.

    • Side effects:
      • Nausea or abdominal discomfort; systemic toxicity is less likely with low oral absorption but can occur.

      • Nephrotoxicity or ototoxicity can occur with significant systemic exposure, particularly with inflamed bowel or impaired renal function.

      • Hypersensitivity; infusion-like flushing reactions are reported rarely with oral therapy and are more characteristic of IV administration.

    • Clinical role:
      • Acceptable treatment for nonfulminant CDI; high-dose oral/enteral therapy is central in fulminant disease, with IV metronidazole and possible rectal vancomycin for ileus. IV vancomycin alone does not treat luminal CDI.

  • Fidaxomicin

    • Mechanism:
      • Inhibits bacterial RNA polymerase, leading to selective bactericidal activity against Clostridioides difficile with minimal impact on normal flora.

    • Side effects:
      • Nausea

      • Abdominal pain

      • Vomiting

    • Clinical role:
      • Preferred for many initial and recurrent nonfulminant adult CDI episodes when accessible; reduces recurrence compared with standard vancomycin. Not the established regimen for fulminant CDI.

  • Metronidazole

    • Mechanism:
      • Reduced intracellular metabolites damage microbial DNA in susceptible anaerobic organisms.

    • Side effects:
      • Peripheral neuropathy

      • Metallic taste

      • Disulfiram-like reaction

    • Clinical role:
      • Oral alternative only for selected nonsevere initial CDI when preferred drugs are unavailable; IV adjunct in fulminant disease, especially with ileus. Avoid repeated/prolonged courses when possible because of neurotoxicity.

Non-pharmacological Treatments

  • Stop the inciting antibiotic when clinically feasible, or narrow essential treatment; also provide targeted CDI therapy when indicated.

  • Supportive care including fluid and electrolyte replacement to manage dehydration.

  • Selected recurrent CDI may benefit from screened microbiota-based therapy after antibiotics, including conventional FMT or approved products. Expert centers may consider conventional FMT for severe/fulminant disease unresponsive to antibiotics; assess surgical needs urgently.

Prevention


Pharmacological Prevention

  • Do not routinely give vancomycin or fidaxomicin to everyone receiving antibiotics. Selected secondary prophylaxis may be considered for patients with recurrent CDI and high risk, balancing uncertain benefit, microbiome effects and resistance.

  • Probiotics are not routinely advised to prevent initial or recurrent CDI; benefit is uncertain and susceptible patients can develop infection from probiotic organisms.

  • Avoidance of unnecessary broad-spectrum antibiotics minimizes disruption of normal microbiota.

  • Bezlotoxumab neutralizes toxin B and previously reduced recurrence in selected patients, but is no longer commercially available in the United States. Approved microbiota products such as Vowst/Rebyota prevent recurrence in eligible adults after antibiotics for recurrent CDI; they do not replace acute treatment.

Non-pharmacological Prevention

  • Strict hand hygiene with soap and water to remove spores effectively.

  • Contact precautions including gloves and gowns in healthcare settings prevent transmission.

  • Environmental cleaning with sporicidal agents reduces contamination of surfaces.

  • Minimizing unnecessary antibiotic use through stewardship programs.

  • Isolation of infected patients to limit spread in hospitals and nursing homes.

Outcome & Complications


Complications

  • Toxic megacolon is a life-threatening dilation of the colon.

  • Colonic perforation can lead to peritonitis and sepsis.

  • Fulminant colitis can cause systemic inflammation, organ dysfunction and shock; bloodstream spread of C. difficile is not the usual mechanism.

  • Recurrent infection occurs in up to 20% of cases after initial treatment.

  • Electrolyte imbalances and dehydration can cause acute kidney injury.

Short-term Sequelae Long-term Sequelae
  • Persistent diarrhea and dehydration requiring fluid resuscitation.

  • Electrolyte disturbances such as hypokalemia from ongoing losses.

  • Severe illness may require hospitalization for fluids, monitoring and oral/enteral CDI therapy; IV metronidazole is an adjunct in fulminant disease.

  • Need for surgical intervention in cases of toxic megacolon or perforation.

  • Recurrence of symptoms within weeks after initial resolution.

  • Persistent bowel symptoms after treatment may reflect recurrence or post-infectious dysfunction; do not assume ongoing infectious colitis from symptoms or a persistently positive PCR alone.

  • Increased risk of recurrent C. difficile infection after initial episode.

  • Post-infectious irritable bowel syndrome can persist after resolution.

  • Colonic strictures or fibrosis are rare but possible after severe inflammation.

  • Psychological impact from repeated illness and hospitalization.

Differential Diagnoses


Antibiotic-Associated Colitis (Clostridioides difficile) versus Inflammatory Bowel Disease (Ulcerative Colitis and Crohn Disease)

Antibiotic-Associated Colitis (Clostridioides difficile)

Inflammatory Bowel Disease (Ulcerative Colitis and Crohn Disease)

Symptoms commonly follow recent antibiotic exposure

IBD can flare with or without antibiotic exposure, and CDI may coexist.

Acute onset of diarrhea and colitis symptoms

IBD usually has a chronic relapsing course, but acute severe flares can mimic or accompany infection.

Compatible symptoms plus appropriately interpreted stool testing support CDI; PCR detects genes, not free toxin.

Endoscopy and biopsy support IBD; evaluate for superimposed CDI during new/worsening diarrhea.

Antibiotic-Associated Colitis (Clostridioides difficile) versus Ischemic Colitis

Antibiotic-Associated Colitis (Clostridioides difficile)

Ischemic Colitis

Can affect adults of any age, often after antibiotic use

Typically affects older adults with vascular risk factors

Profuse watery diarrhea with or without blood, often persistent

Sudden abdominal pain followed by bloody diarrhea, often transient ischemia

CT may show pancolitis or colonic wall thickening without vascular distribution

CT shows segmental bowel wall thickening with thumbprinting in watershed areas

Antibiotic-Associated Colitis (Clostridioides difficile) versus Viral Gastroenteritis

Antibiotic-Associated Colitis (Clostridioides difficile)

Viral Gastroenteritis

Recent antibiotic use is a key risk factor

Recent exposure to contaminated food or water or sick contacts

Diarrhea often lasts longer and may be severe with pseudomembranous colitis

Self-limited illness lasting 1-3 days with vomiting and watery diarrhea

Interpret toxin/NAAT results with symptoms and competing causes.

Viral gastroenteritis is often diagnosed clinically; viral PCR is reserved for selected settings, and a negative C. difficile toxin assay alone does not prove a viral cause.

Antibiotic-Associated Colitis (Clostridioides difficile) versus Antibiotic-Associated Diarrhea (Non-C. difficile)

Antibiotic-Associated Colitis (Clostridioides difficile)

Antibiotic-Associated Diarrhea (Non-C. difficile)

Overgrowth of toxigenic Clostridioides difficile strains

Antibiotic-related diarrhea may occur without toxin-mediated CDI, even if incidental C. difficile colonization is present.

Compatible illness with appropriate toxin/toxigenic testing.

No convincing evidence of toxin-mediated CDI after clinical and laboratory assessment; a single insensitive negative toxin assay is not definitive.

CDI severity ranges from mild diarrhea to fulminant colitis; pseudomembranes are not required.

Mild diarrhea that resolves with discontinuation of antibiotic

Antibiotic-Associated Colitis (Clostridioides difficile) versus Microscopic Colitis

Antibiotic-Associated Colitis (Clostridioides difficile)

Microscopic Colitis

Can affect adults of any age, often after antibiotic exposure

Typically affects older adults, especially women

Pseudomembranes may be present but endoscopy is not routine or required.

Colonoscopy often looks normal; biopsies show increased intraepithelial lymphocytes or a thickened subepithelial collagen band, depending on subtype.

Often acute onset with systemic symptoms like fever and leukocytosis

Chronic watery diarrhea without systemic toxicity